| 今开：0.0 | 昨收：0.0 |
| 最高：0.0 | 最低：0.0 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：5.52493E7 |
药渡2018-01-30 21:38
为贯彻落实中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》（厅字﹝2017﹞42号）的要求，引导仿制药研发生产，提高公众用药可及性，我中心筛选出依鲁司他等9个国内化合物专利权到期、终止、无效且尚无仿制申请的国外已上市且具有明确临床价值的药品，现纳入...查看全文
深思远见2015-07-12 22:39
$Aegerion制药(AEGR)$近期评级信息如下：
20150706 Guggenheim Securities 降级， 评级：中性->卖出，
更多分析和资讯，请关注微-信-公-众-号 stock_tong查看全文
$Aegerion制药(AEGR)$ 美东时间 2016-05-16 16:30 After Market Close:AEGERION PHARMA Earning Release . Wall St EPS Est ($):-0.54. 网页链接
$Aegerion制药(AEGR)$ 8-K - Current report Filed: 2016-05-12 AccNo: 0001104659-16-120275 Size: 59 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Aegerion制药(AEGR)$ NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB Filed: 2016-05-11 AccNo: 0001104659-16-120125 Size: 63 KB 网页链接
$Aegerion制药(AEGR)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-05-10 AccNo: 0000315066-16-005831 Size: 9 KB 网页链接
$Aegerion制药(AEGR)$ 美东时间 2016-06-28 09:00 Aegerion Pharmaceuticals Inc Annual Shareholders Meeting 网页链接
$Aegerion制药(AEGR)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2016-05-03 AccNo: 0001104659-16-117035 Size: 388 KB 网页链接
$Aegerion制药(AEGR)$ DEF 14A - Other definitive proxy statements Filed: 2016-04-29 AccNo: 0001047469-16-012755 Size: 835 KB 网页链接
$Aegerion制药(AEGR)$ 美东时间 2016-06-24 09:00 Aegerion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) 网页链接
$Aegerion制药(AEGR)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2016-03-22 AccNo: 0000899140-16-001327 Size: 74 KB 网页链接
$Aegerion制药(AEGR)$ 8-K - Current report Filed: 2016-03-22 AccNo: 0001104659-16-106747 Size: 20 KBItem 1.01: Entry into a Material Definitive Agreement 网页链接